此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项关于ASP546C在成人胃食管癌、胰腺癌或其他实体瘤患者中的研究

2026年11月12日 更新者:Astellas Pharma Global Development, Inc.

一项1b/2期开放标签研究,旨在评估ASP546C在表达CLDN18.2的局部晚期不可切除或转移性胃食管腺癌、胰腺腺癌或其他实体瘤类型参与者中的安全性和疗效

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach.

This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion.

In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C.

In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C.

People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.

研究概览

研究类型

介入性

注册 (估计的)

150

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Chiba
      • Kashiwa-shi、Chiba、日本
        • 招聘中
        • National Cancer Center Hospital East
    • Tokyo
      • Chuo-ku、Tokyo、日本
        • 招聘中
        • National Cancer Center Hospital
      • Koto-ku、Tokyo、日本
        • 招聘中
        • The Cancer Institute Hospital of JFCR
    • Alabama
      • Birmingham、Alabama、美国、35249
        • 招聘中
        • UAB Medicine - UAB Hospital
    • California
      • Los Angeles、California、美国、90025
        • 招聘中
        • START Los Angeles
      • Orange、California、美国、92868
        • 招聘中
        • UC Irvine Health-Chao Family Comprehensive Cancer Center
    • Florida
      • Miami、Florida、美国、33176
        • 招聘中
        • Miami Cancer Institute
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Winship Cancer Institute at Emory University
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • 招聘中
        • Indiana University (IU) Health - Multi-D Oncology Clinic
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Barbara Ann Karmanos Cancer Center
      • Grand Rapids、Michigan、美国、49546
        • 招聘中
        • START Midwest
    • Minnesota
      • Saint Louis Park、Minnesota、美国、55426
        • 招聘中
        • Health Partners Frauenshuh Cancer Center
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • 招聘中
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering Basking Ridge
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • Hackensack University Medical Center
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Cancer Center Monmouth
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen
      • New Brunswick、New Jersey、美国、08903
        • 招聘中
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Commack
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester
      • Lake Success、New York、美国、10042
        • 招聘中
        • START New York
      • Long Island City、New York、美国、11101
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
      • Uniondale、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke Cancer Center Durham
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73120
        • 招聘中
        • Mercy Coletta Cancer Center
    • Texas
      • Austin、Texas、美国、78758
        • 招聘中
        • Next Oncology - Austin
      • Houston、Texas、美国、77054
        • 招聘中
        • Next Oncology - Houston
      • Irving、Texas、美国、75039
        • 招聘中
        • Next Oncology - Dallas
      • San Antonio、Texas、美国、78229
        • 招聘中
        • START San Antonio (STSA)
    • Utah
      • Salt Lake City、Utah、美国、84112
        • 招聘中
        • Huntsman Cancer Institute University of Utah
      • West Valley City、Utah、美国、84119
        • 招聘中
        • START Mountain Region
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Inova Schar Cancer Institute Clinical Trials
    • Washington
      • Seattle、Washington、美国、98101
        • 招聘中
        • Virginia Mason Medical Center
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • UW Health Carbone Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participant has a histologically confirmed diagnosis of gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma, or pan-tumor (cholangiocarcinoma, colorectal adenocarcinoma, NSCLC [adenocarcinoma], SCLC, ovarian mucinous carcinoma or invasive breast cancer [ER/PR+HER2-; ER/PR-HER2+; ER/PR+HER2+ (triple positive); ER/PR-HER2- (triple negative)].

  • Participant has radiologically confirmed uLA/m gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma or pan-tumor within 28 days prior to the first dose of study intervention.

  • Cohorts 1 to 3 only: Participant has measurable disease according to RECIST v1.1 within 28 days prior to the first dose of study intervention. For participants with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.

  • Cohort 4 only: Participant has radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, within 28 days prior to the first dose of study intervention. For participants with only 1 evaluable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.

  • Participant's tumor expresses CLDN18.2.

  • Participant has received at least 1 line of therapy for uLA/m disease.

  • Participant has an ECOG performance status of 0 or 1.

  • Participant has a predicted life expectancy >= 12 weeks.

  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a women of childbearing potential (WOCBP)
    • WOCBP who has a negative urine or serum pregnancy test at screening (Specific to Japan: with a medical interview), and agrees to follow the contraceptive guidance from the time of informed consent through at least 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.

  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration.

  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Male participant must not donate sperm during the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration.

  • Participant must meet all of the criteria based on the locally analyzed laboratory tests collected within 14 days prior to the first dose of study intervention. In case of multiple local laboratory tests within this period, the most recent data should be used.

  • Participant is willing to provide or has sufficient tumor tissue for central biomarker assessment.

  • Participant agrees not to participate in another interventional study while receiving study intervention in the present study.

Exclusion Criteria:

  • Cohorts 1, 2 and 3 only: Participant's disease is of the non-adenocarcinoma histology or mixed histology containing adenocarcinoma.

  • Cohorts 1, 2 and 3 only: Participant has received > 2 prior lines of therapy for uLA/m disease.

    • Participants in Cohort 4 (pan-tumor) may enroll regardless of the number of prior lines of therapy, if they are not eligible for, decline, or do not have any available standard of care treatment options.
  • Participant has complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting.

  • Participant has significant gastric bleeding or had a significant bleeding episode from the gastrointestinal tract within 3 months prior to the first dose of study intervention and/or an untreated peptic ulcer disease that would preclude the participant from participation.

  • Participant has significant bleeding disorders or has had vasculitis within 3 months prior to the first dose of study intervention.

  • Participant has a history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of study intervention.

  • Participant has symptomatic, untreated brain metastases or meningeal carcinomatosis (carcinomatous meningitis) from the primary malignancy. A participant with stable central nervous system metastases for > 3 months without need of steroids for >= 2 weeks prior to the first dose of study intervention is eligible.

  • Participant has a past or current mental illness that is difficult to control.

  • Participant has unresolved pneumonitis or a history of non-infectious pneumonitis such as immune-related pneumonitis or radiation-induced pneumonitis for which the participant is taking glucocorticoids or needed glucocorticoids within 6 months prior to the first dose of study intervention.

  • Participant has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen [HBsAg]) or hepatitis C infection. Screening for these infections should be conducted if indicated per local requirements.

    • If participant is negative for HBsAg, but hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) positive, a hepatitis B DNA test will be performed; if the test is positive, the participant will be excluded.
    • Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results, is eligible.
    • Participant treated for HCV with undetectable viral load results is eligible.
  • Participant has an active infection requiring systemic therapy that has not completely resolved within 7 days prior to the first dose of study intervention.

  • Participant has a malignancy for which treatment is required, has a history of another malignancy within the past 5 years, except malignancies for which participant received curative therapy without recurrence for the last 5 years (e.g., adequately resected non-melanoma skin cancer, localized prostate cancer), or had treatment for carcinoma in situ.

  • Participant has clinically significant third spacing (large amount of pleural fluid or ascites) that requires frequent percutaneous draining or requires placement of a drainage catheter for adequate control.

  • Participant has any AE from prior antitumor treatments that has not yet recovered to grade 0 or 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 (except alopecia).

  • Participant has an active autoimmune disease or other medical condition that has required high dose systemic steroids at the time of screening.

  • Participant has known peripheral neuropathy > grade 1 (except when the sole neurological abnormality is absence of deep tendon reflexes).

  • Participant has sinusoidal obstruction syndrome, formerly known as veno-occlusive disease; if present, should be stable or improving.

  • Participant has significant cardiovascular disease, including any of the following:

    • Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to the first dose of study intervention.
    • History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes), cardiac arrhythmias requiring anti-arrhythmic medications (a participant with rate controlled atrial fibrillation for > 1 month prior to the first dose of study intervention is eligible) or obligate use of cardiac pacemaker.
    • QTc interval > 470 msec
    • Documented history or family history of congenital long QT syndrome.
  • Participant has ongoing or previous interstitial lung disease, active diverticulitis or solid organ or stem cell transplant.

  • Participant has a serious non-healing wound or bone fracture within 28 days prior to study intervention.

  • Participant has had a major surgical procedure within 28 days prior to the first dose of study intervention and has not completely recovered from the surgical procedure <= 14 days prior to the first dose of study intervention.

  • Participant has received chemotherapy, immunotherapy or investigational therapy <= 14 days prior to the first dose of study intervention and has not recovered from any related toxicity. Palliative radiotherapy is allowed and must be completed > 14 days prior to the first dose of study intervention.

  • Participant has received prior CLDN18.2 ADC. Prior treatment with CLDN18.2 monoclonal antibody or bi-specific T-cell engager is allowed.

  • Participant has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.

  • Participant has a known or suspected hypersensitivity to ASP546C or any components of the formulation used.

  • Participant has a clinically significant disease or comorbidity that in the opinion of the investigator may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation.

  • Cohorts 1 and 2 (gastroesophageal adenocarcinoma) only: Participant has known HER2 positive status defined as immunohistochemistry (IHC) 3+ or IHC 2+/ in situ hybridization (ISH) +. ISH positive is defined as HER2/ chromosome enumeration probe 17 (CEP17) ratio ≥ 2.0 or an average HER2 copy number ≥ 6.0 signals/cell.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1 - Cohort 1 ASP546C Lower Dose

Participants with unresectable locally advanced or metastatic (uLA/m) gastroesophageal adenocarcinoma will receive a lower dose of ASP546C intravenously, once every 3 weeks (Q3W).

Intravenous administration

其他名称:
  • XNW27011
实验性的:Part 1 - Cohort 2 ASP546C Higher Dose

Participants with uLA/m gastroesophageal adenocarcinoma will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

其他名称:
  • XNW27011
实验性的:Part 2 - Cohort 3 ASP546C Higher Dose

Participants with uLA/m pancreatic adenocarcinoma will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

其他名称:
  • XNW27011
实验性的:Part 2 - Cohort 4 ASP546C Higher Dose

Participants with pan-tumor (cholangiocarcinoma, colorectal adenocarcinoma, NSCLC, SCLC, ovarian mucinous carcinoma or invasive breast cancer) will receive a higher dose of ASP546C intravenously, once Q3W.

Intravenous administration

其他名称:
  • XNW27011

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
大体时间:Up to 36 Months

ORR is defined as the proportion of participants who have a best overall response (BOR) of complete response (CR) or partial response (PR) as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug Conjugate
大体时间:Up to 39 Months

ADC concentrations will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax)
大体时间:Up to 39 Months

Cmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d)
大体时间:Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1: Number of participants with Adverse events (AEs)
大体时间:Up to 39 Months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

Up to 39 Months
Part 1: Number of Participants with Vital Sign Abnormalities and/or AEs
大体时间:Up to 39 Months

Number of participants with potentially clinically significant vital sign values.

Up to 39 Months
Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEs
大体时间:Up to 39 Months

Number of participants with potentially clinically significant laboratory values.

Up to 39 Months
Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Scores
大体时间:Up to 39 Months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 39 Months

次要结果测量

结果测量
措施说明
大体时间
Part 1 and Part 2: ORR per Investigator-assessed per RECIST v1.1
大体时间:Up to 36 Months

ORR is defined as the proportion of participants who have a BOR of CR or PR as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1 and Part 2: Disease Control Rate (DCR) per Investigator-assessed per RECIST v1.1
大体时间:Up to 36 Months

DCR defined as the proportion of participants with a BOR of CR, PR or stable disease (SD) as per investigator assessment per RECIST v1.1.

Up to 36 Months
Part 1 and Part 2: Duration of Response (DOR) per Investigator-assessed per RECIST v1.1
大体时间:Up to 36 Months

DOR is defined as the time from the date of the first response (CR/PR) until the date of radiologic disease progression as per investigator assessment per RECIST v1.1 or date of death from any cause, whichever is earlier.

Up to 36 Months
Part 1 and Part 2: Progression Free Survival (PFS) per Investigator-assessed per RECIST v1.1
大体时间:Up to 39 Months

PFS is defined as the time from the date of first dose until the date of radiologic disease progression as per investigator assessment per RECIST v1.1 or death from any cause, whichever is earlier.

Up to 39 Months
Part 1 and Part 2: Overall Survival (OS)
大体时间:Up to 39 Months

OS is defined as the time from the date of first dose until the documented date of death from any cause

Up to 39 Months
Part 2: Number of Participants with AEs
大体时间:Up to 39 Months

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

Up to 39 Months
Part 2: Number of Participants with Vital Sign Abnormalities and/or AEs
大体时间:Up to 39 Months

Number of participants with potentially clinically significant vital sign values.

Up to 39 Months
Part 2: Number of Participants with Laboratory Value Abnormalities and/or AEs
大体时间:Up to 39 Months

Number of participants with potentially clinically significant laboratory values.

Up to 39 Months
Part 2: Number of Participants at Each Grade of ECOG Performance Status Scores
大体时间:Up to 39 Months

The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

Up to 39 Months
Part 1 and Part 2: Change from baseline in Expression Levels of Claudin 18.2 (CLDN18.2)
大体时间:Baseline and up to Day 58

Comparison of CLDN18.2 expression at baseline versus on-treatment tumor biopsies will be performed.

Baseline and up to Day 58
Part 1 and Part 2: PK of ASP546C ADC: Concentration at the End of Infusion (CEOI)
大体时间:Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: CEOI
大体时间:Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: CEOI
大体时间:Up to 39 Months

CEOI will be recorded from the PK serum samples collected.

Up to 39 Months
Part 2: PK of ASP546C ADC: AUC0-21d
大体时间:Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: AUC0-21d
大体时间:Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: AUC0-21d
大体时间:Up to 39 Months

AUC0-21d will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Trough Concentration (Ctrough)
大体时间:Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: Ctrough
大体时间:Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: Ctrough
大体时间:Up to 39 Months

Concentration immediately prior to dosing at multiple dosing (Ctrough) will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Time of Maximum Concentration (tmax)
大体时间:Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: tmax
大体时间:Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: tmax
大体时间:Up to 39 Months

tmax will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Terminal Elimination Half-life (t1/2)
大体时间:Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: t1/2
大体时间:Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: t1/2
大体时间:Up to 39 Months

t1/2 will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Clearance (CL)
大体时间:Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: CL
大体时间:Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: CL
大体时间:Up to 39 Months

CL will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C ADC: Volume of Distribution at Steady State (Vss)
大体时间:Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Unconjugated Payload: Vss
大体时间:Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: PK of ASP546C Total Antibody: Vss
大体时间:Up to 39 Months

Vss will be recorded from the PK serum samples collected.

Up to 39 Months
Part 1 and Part 2: Number of Participants with all Anti-drug Antibodies (Total Antibody and ADC) Against ASP546C
大体时间:Up to 22 Months

Number of participants with anti-drug antibodies will be reported.

Up to 22 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Physician、Astellas Pharma Global Development, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月4日

初级完成 (估计的)

2029年7月31日

研究完成 (估计的)

2029年7月31日

研究注册日期

首次提交

2026年3月18日

首先提交符合 QC 标准的

2026年3月18日

首次发布 (实际的)

2026年3月23日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

IPD 共享时间框架

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

IPD 共享访问标准

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅